Background: Lipofilling is performed in breast cancer patients to optimize the aesthetic outcome following breast reconstruction after mastectomy. Despite its common usage worldwide, little is known about the interaction of the lipoaspirate and dormant cancer cells. Up to date, no risk factors that increase the risk for cancer recurrence have been established. This study aims to identify risk factors for lipofilling candidates after breast cancer and questions the oncological safety of lipofilling in lymph node positive disease.
Introduction
Lipofilling for contour corrections or volume restorations after breast reconstruction has emerged to be a standard in common practice (1) . Sixty-two percent of surveyed members of the American Society of Plastic Surgeons (ASPS) use this technique for breast reconstruction purposes for which volume deficiencies especially in the upper medial quadrant of the reconstructed breast are the most common indication (2) . Despite of fat being biocompatible, non-immunogenic and a natural filler, concerns on its oncological safety persist in breast cancer patients undergoing mastectomy and reconstruction (3) (4) (5) (6) . In vitro studies have shown the lipoaspirate to be a bioactive substance whose adiposederived stem cells (ADSCs) are capable of cell stimulation and tissue regeneration by the secretion of numerous factors (7) (8) (9) that also promote cancer growth, angiogenesis and alter the antitumor immune response (10) when in close vicinity to breast cancer cells. Thus experimental studies demonstrated a potential risk of lipofilling to cause cancer recurrence as ADSCs may stimulate quiescent cancer cells still resident after surgery (11) (12) (13) . Particularly one retrospective study points to an increased risk for locoregional recurrence after mastectomy for ductal carcinoma in situ (DCIS) or breast conservative therapy (5, 6) . In 2007 the ASPS declared a Fat Graft Task Force that strongly emphasized the need for more research to prove oncological safety of lipofilling (14) , in 2012 the Patient Safety Committee demanded for more evidencebased guidance for the safety of fat grafting to the postmastectomy reconstructed breast (15) . Up to date, there is a limited amount of studies showing evidence of lipofilling to be oncological safe. Recently a multicenter casecohort study (16) and a matched controlled study (17) demonstrated that fat transfer in breast cancer patients who underwent mastectomy, was not associated with a higher risk of cancer recurrence. Yet, none of the studies so far, has focused on determining and analyzing potential patient risk factors that could work in synergy with the lipoaspirate and might increase the risk of cancer recurrence. Up to date, risk factors for recurrence in breast cancer patients undergoing a delayed deep inferior epigastric perforator (DIEP)-flap reconstruction and subsequent lipofilling have not been assessed in the literature. Further, very little is known about the interaction of ADSCs and dormant cancer cells in form of occult (micro) metastases. Thus, the purpose of this study is to identify potential risk factors for this patient cohort and improve patient selection for fat grafting procedures.
Methods

Study population
The study is a matched retrospective cohort study. All patients that underwent a lipofilling between 2009 and 2013 at the Department of Plastic and Reconstructive Surgery at the SANA Klinik in Düsseldorf were identified through a prospectively maintained hospital database. Only breast cancer patients treated with total mastectomy and delayed DIEP-flap reconstruction were eligible. Patients with immediate breast reconstruction, bilateral breast cancer, other reconstructive method than the DIEPflap, or prophylactic mastectomy were excluded. Further, patients were not allowed to have a cancer recurrence between the time interval of their primary surgery (mastectomy), their delayed DIEP-flap reconstruction and their lipofilling ( Figure 1) . In total, one hundred patients met the inclusion criteria and were selected for the study. For each of these patients, a control patient was selected from the same database. A matched control patient underwent a total mastectomy for breast cancer and a delayed breast reconstruction with the DIEPflap, but did not undergo subsequent lipofilling and was recurrence-free from the primary oncological surgery up to the startpoint of the study follow-up ( Figure 1 ). The patient match was performed 1:1 and included following categorical characteristics: age (within 5 years), year of primary oncological surgery (within 3 years), year of DIEPflap reconstructive surgery (within 3 years), primary tumor histopathology (DCIS, invasive lobular, invasive ductal), receptor status (estrogen, progesterone, Her-2/neu), tumor stage (TNM) and grade (G). Further, risk factors for cancer recurrence were determined from the literature and according to these, the whole study population was subdivided into risk factor-subgroups, which were categorized as patient-dependent-factors (PDFs) and tumor-dependentfactors (TDFs) ( Table 1 ). The study-specific follow-up started for each matched lipofilling and control patient with the date of the lipofilling procedure. This was labeled as the "startpoint" (Figure 1) . A recurrence was defined as an event involving local, regional or distant relapse. The detection of a recurrence or death was considered the end of the followup period. To control and confirm breast cancer recurrence, a questionnaire to each patient was sent out, addressing questions if, when and where a recurrence has occurred. An informed consent was also included in the letter. When the patient did not respond, she was contacted by telephone. In case of unavailability, she was considered lost-to-follow-up and marked as "not available".
Fat grafting technique
In all patients the fat harvesting technique after Coleman was used (18) (19) (20) (21) .
Statistical analyses
All statistical analyses were performed using the R software (The R development Core Team 2004; Free Software Foundation, Boston, MA) and the SAS package (SAS Institute, Cary, NC). Chi-square test was performed to assess potential differences between the lipofilling and control groups and to ensure homogeneity. The Log-Rank test was used to compare the follow-up times in different subgroups and the results are presented in Kaplan-Meier curves. Univariate Cox proportional hazard regression models were used to evaluate the association of potential risk factors (PDFs, TDFs) with the time to recurrence. The results were expressed as hazard ratios (HR) with 95% confidence interval (CI). All tests were two-sided and P-values below 0.05 were considered as statistically significant.
Results
The median follow-up from the date of mastectomy until the end of follow up in the lipofilling and control groups was 72.5 months (range 25-173 months) and 76.5 months (range 28-151 months), respectively. The median follow-up from the startpoint was 32 months (range 11-67 months) in the lipofilling and 31 months (range 7-63 months) in the control group ( Table 2 ). The median age in both groups was around 50 years. There were 29% overweight patients in the lipofilling group and 52% in the control group. More patients in our population were non-smoking and had a negative family history of breast cancer (17% and 21% smokers, 30% and 34% with positive family history in the lipofilling and the control group, respectively). Around 80% received chemotherapy and more than half received radiotherapy ( Table 3) . A total of 182 of the tumors were invasive and only 18 were DCIS ( Table 4) . Node-positive disease was in 47% and 35%, tumor size T2-T3 in 57% and 54%, grade G2-G3 in 88% and 80% patients in the lipofilling and the control group, respectively. Tumor morphology was equal in the both Only patients from the lipofilling group underwent a lipofilling procedure whose date was taken as the startpoint to measure the followup time (survival time) for both groups. A criterion of inclusion into both groups was a disease-free time period between the primary oncological surgery and the startpoint of the follow-up time. Table 4 ). The subgroup survival analysis by the means of the log rank test showed that lipofilling increased the risk of recurrence in women that had a breast cancer with a high-grade neoplasia (G3) (P=0.049) and a positive nodal status (P=0.035) (Figure 3 ).
Discussion
In contrast to previous studies that have analyzed the cancer recurrence risk of fat grafting in patients that underwent mastectomy/partial mastectomy with either prosthetic or autologous breast reconstruction, this study focuses only on breast cancer patients after mastectomy with a delayed DIEP-flap reconstruction. Up to date, this study is the only one addressing risk factors for this particular study cohort. The overall analysis of the oncological safety of lipofilling in breast cancer patients after delayed DIEP-flap reconstruction following mastectomy does not show any significant difference in the DFS between the lipofilling and control group. This finding is in concordance with the estimated HR stating that lipofilling poses no risk of recurrence on the mentioned study population. According to past literature, a few studies have evaluated the oncological safety and follow-up in patients with breast cancer who underwent lipofilling following mastectomy and reconstruction resulting in not congruent results. Thus, the evidence of oncological safety still remains uncertain, especially when 49% of surveyed members of the ASPS stated that the lack of evidence concerning the impact lipofilling has on breast cancer development or recurrence withholds them to practice the method (2). Petit et al. (5) was the first to discuss the controversy about the safety of lipofilling in breast cancer patients. Like in this present study, they matched patients who underwent lipofilling with control patients that did not obtain lipofilling. However, while Petit et al. performed the study on a population having both breast conserving surgery (39%) and mastectomy (61%), the patient population in this study addressed only patients after mastectomy undergoing a delayed breast reconstruction with a DIEP-flap, making it more homogenous. Nevertheless, their findings were (22) or an implant-based reconstruction. Recently two papers (16, 17) have emerged assessing the overall risk of fat grafting on a large scale study population and they also support the oncological safety of the procedure in breast reconstruction. Yet, in one of them (16) patients below 50 years, with a Ki-67 value greater than or equal to 14 and a high-grade neoplasia were associated with an increased recurrence rate after lipofilling. Also in the study by Petit et al. (6) concerning fat grafting safety in patients with only intra-epithelial neoplasia, patients below 50 years, a Ki-67 value greater than or equal to 14 and a highgrade neoplasia were at increased risk of local recurrence following fat grafting. Also the subgroup analysis in this study shows patients with a high-grad neoplasia (G3) or a positive nodal status to be more susceptible to an increased risk of recurrence after breast reconstruction induced by lipofilling. Gland Surg 2017;6(4):315-323 gs.amegroups.com 
Grading
The recurrence rate for G3 neoplasias in the study by Petit and his colleagues resulted in 19% for the lipofilling group (3 events) and no events in the control group. This result is in line with the findings in our study, since lipofilling patients with a high-grade neoplasia had a recurrence rate of 16% (5 events) in comparison with the control group that presented with no events. Generally, poorly differentiated cancers are proven to have a worse patient survival than low-grade malignancies. This can be seen in studies such as the one by Bijker et al. (23) where patients with DCIS were treated by local excision with or without consecutive radiation. Factors significantly associated with an increased local recurrence risk were poorly differentiated DCIS. In the randomized analysis by Johansen et al. (24) , patients with Grade 2-3 breast cancer had a worse survival than patients with Grade 1 tumors. Thus, the higher the Grade, the more aggressive are the tumor cells (25) and therefore in theory eventually easier susceptible to environmental cues such as lipofilling, if any would remain after surgery in form of occult micrometastases or as dormant cell in metastatic niches (26) .
Nodal status
The nodal status is one of the most important prognostic factors predictive of recurrence and survival in breast cancer (27) . There is a direct positive relationship between the number of involved axillary lymph nodes and the risk for distant recurrences (28) . As the number of lymph nodes metastases increases, the risk of cancer recurrence increases and the survival decreases (29) . For breast cancer cells to metastasize , they must take either a haematogenous or lymphatic route to disseminate to the tissues. In case of haematogenous spread, the cells have to pass through the basement membrane to relocate themselves. During this movement, they can get trapped in the endothelium of the microvasculature which constitutes a niche that induces cancer cell quiescence/dormancy via thrombospondin-1 (TSP-1). Yet, once growth of the vasculature is induced, the endothelium looses its tumor-suppressive nature by the reduced expression of TSP-1 and enhanced expression of periostin (POSTN) and transforming growth factor-β1 (TGF-β1) that promote neovascularization but at the same time activate the cancer cells to proliferate (26, 30, 31) . ADSCs secrete a number of vascular endothelial growth factors (VEGFs) that induce neovascularization but can also stimulate lymphangiogenesis (32) . Thus, fat grafting might be indirectly able to reactive dormant cancer cells in their niche by causing the vasculature to grow. Patients with a known node positive disease have an increased risk of occult micro-metastases hidden in their lymph nodes (33, 34) . If similar mechanism applies to dormant breast cancer cells in lymphnodes/lymphatic vessels as in the vasculature, then lipofilling that is applied in the near vicinity of such lymph nodes, might in theory, initiate proliferation of the dormant cancer cells and therefore provoke a recurrence through VEGFs released by the adipocytes and ADSCs. There are only five recurrences in the whole node positive study population (lipofilling and control) and they are found to be only in the lipofilling group, potentially being stimulated by the lipoaspirate. The strengths of the study lie in its matched cohort design and homogeneous patient population. The retrospective nature of the study and insufficient information about adjuvant therapy and mastectomy technical aspects are a limitation. It should be taken into consideration that the results from the subgroup analysis 
Conclusions
In summary, lipofilling does not seem to increase the risk of breast cancer recurrence more than a DIEP-tissue flap. Thus, autologous fat grafting remains an attractive proposition for women wishing to optimize their aesthetic outcomes after breast reconstruction with a free flap. However, the subgroup analysis revealed a node positive disease and/or a high grade neoplasia to increase the risk of recurrence when they coexisted with the lipoaspirate. Yet, before withholding fat grafting as a reconstruction option in the above mentioned patient groups, more randomized controlled studies with a larger sample size would be required to determine clinical significance and re-evaluate the need to improve patient selection for fat grafting procedures. Further, tumor dormancy awakening remains very poorly understood and requires additional studies, especially in regards to fat grafting. Currently, there are sparse publications addressing this topic.
